Therapeutic Efficacy of Cefodizime

Cefodizime has apparent ability in the analysis of high and lower respiratory amplitude infections, urinary amplitude infections and gonorrhoea in allusive and noncomparative trials. Cefodizime 2 to 4 g/day in 1 to 2 doses daily, administered intravenously or intramuscularly for an boilerplate of 7 to 10 days, eradicated H. influenzae, K. pneumoniae, non-β-lactamase-producing M. catarrhalis, and S. pneumoniae in patients with pneumonia and added lower respiratory amplitude infections. Cefodizime was clinically able in 80 to 100% of these patients and bacterial abolishment ante (89 to 98%) paralleled analytic efficacy. In the few allusive trials reported, analytic and bacteriological success ante of cefodizime were agnate to those of ceftriaxone, cefuroxime and cefotaxime. In accouchement and aged patients with lower respiratory amplitude infections, cefodizime analysis accomplished acceptable analytic after-effects in 86 to 100% and 87.5% of patients, respectively. Agnate analytic cure ante were empiric in the analysis of high respiratory amplitude infection in noncomparative trials undertaken primarily in children.
Cefodizime 1 to 2 g/day in individual or disconnected doses for 7 to 9 canicule (mean) resulted in analytic cure in 86 to 100% of paediatric, developed or aged patients with urinary amplitude infections. In the analysis of complicated and apprehensible urinary amplitude infections, individual dosage analysis with intramuscular cefodizime 1 or 2g resulted in analytic cure in 72 and 88% of patients, respectively. Preliminary affirmation from trials comparing cefodizime with cefuroxime, ceftizoxime and nor-floxacin suggests that cefodizime is as able as these accepted therapies in the analysis of urinary amplitude infection.
A individual intramuscular bang of cefodizime 0.25 to 1g approved about 100% ability in the analysis of urogenital gonorrhoea; cefodizime 0.5 or 1g was as able as a individual dosage of cefotaxime 1g, bearing analytic cure in 100, 100 and 99% of patients, respectively. Cefodizime was able irrespective of the sex of the accommodating or the penicillinase-producing cachet of the N. gonorrhoeae.
Cefodizime has aswell been adjourned in baby noncomparative trials in patients with meningitis, otitis media, gynaecological infections and assorted surgical infections. Administration of cefodizime 100 mg/kg/day to adults or 200 mg/kg/day to accouchement with bacterial meningitis resulted in analytic cure, after sequelae, in 80% of cases. Intravenous cefodizime was clinically able in 88 to 100% of Japanese women with assorted gynaecological infections. Pathogen abolishment ante of 40 to 75% were achieved; Enterococcus faecalis was the a lot of accepted constant organism. The post-operative infection amount in immunocompromised patients administered a individual intramuscular bang of cefodizime 2g 30 account afore belly anaplasty was 5%, compared with 25% in basic patients. Noncomparative trials of intravenous infusions of cefodizime 0.5 to 2g circadian in 2 disconnected doses accept approved analytic cure ante of 65 to 80% in patients with assorted surgical infections. Bacteriological ability was 75 to 85% and 68 to 71% in infections acquired by Gram-negative and Gram-positive bacteria, respectively.
more about:
pharmaceutical chemicals online